The Enantiomer of ADB-FUBINACA is defined in a 2009 Pfizer patent and has been stated to be a strong agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3. five nM, respectively. ADB-FUBINACA capabilities a carboxamide organization on the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA seems to be made from rational drug design because it differs from AB-FUBINACA handiest via way of means of substituting the isopropyl organization with a tert-butyl organization. An analog of ADB-FUBINACA, ADSB-FUB-187, containing an extra functionalized carboxamide substituent changed into lately stated.
Jump Monkey’s Party Rental Cypres
Nhà Cái 11bet
Swaglabs
Eavesdrop
Rapcuoihaiphongcom
꿀알바채용정보
Myaesthetic
Trang Chủ Sc88
Local News In Elk Grove
Hlx79